Ipsen S.A. (IPN.PA)

108,40 +2,10 (+1,98%) Alla chiusura: 05:35PM CEST

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 5.325

Descrizione

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Governance aziendale

L'ISS Governance QualityScore di Ipsen S.A. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 7; diritti degli azionisti: 7; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.